# MilliporeSigma opens $110M viral vector facility in Carlsbad, California

MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, opened a second viral vector contract development and manufacturing facility in Carlsbad, California. The $110 million, 140,000-square-foot facility doubles production capacity for viral gene therapy.

- Type: New facility
- Announced: 2021-10-12
- Where: Carlsbad, California, United States
- Value: $110.0M
- Starts operating: 12 Oct 2021
- Status: completed
- Products: viral vectors for gene therapy
- Sectors: [Specialty Chemicals](https://endata.com/sectors/specialty-chemicals.md)

## Companies

- [MilliporeSigma](https://endata.com/companies/7341.md)
- [Merck KGaA](https://endata.com/companies/1393.md) (partner)

## Sources

- [sigmaaldrich.com](https://www.sigmaaldrich.com/US/en/collections/press/p412283912), 2021-10-12: "This new $110 million, 140,000-square-foot facility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.